ENSG vs MIRM
Ensign Group vs Mirum Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
MIRM
Mirum Pharmaceuticals, Inc.
56
Watch
| Metric | ENSG | MIRM |
|---|
| AI Score |
69
|
56
|
| Price |
$180.10
|
$98.27
|
| P/E Ratio |
27.43×
|
-6.75×
|
| ROE |
15.4%
|
-7.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
81.7%
|
| Debt / Equity |
0.92×
|
-72.97×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
33.9
|
| Beta |
0.694
|
0.507
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus MIRM.
ENSG leads by 13 points.
ENSG scores 69/100 (Buy) versus MIRM at 56/100 (Watch).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
MIRM Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 44.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 13.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 44.0% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 13.0x prices in significant intangible value — Value
- ROE of only -289.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical